Cargando…
FEN1 promotes tumor progression and confers cisplatin resistance in non‐small‐cell lung cancer
Lung cancer is one of the leading causes of cancer mortality worldwide. The therapeutic effect of chemotherapy is limited due to the resistance of cancer cells, which remains a challenge in cancer therapeutics. In this work, we found that flap endonuclease 1 (FEN1) is overexpressed in lung cancer ce...
Autores principales: | He, Lingfeng, Luo, Libo, Zhu, Hong, Yang, Huan, Zhang, Yilan, Wu, Huan, Sun, Hongfang, Jiang, Feng, Kathera, Chandra S., Liu, Lingjie, Zhuang, Ziheng, Chen, Haoyan, Pan, Feiyan, Hu, Zhigang, Zhang, Jing, Guo, Zhigang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5467497/ https://www.ncbi.nlm.nih.gov/pubmed/28371273 http://dx.doi.org/10.1002/1878-0261.12058 |
Ejemplares similares
-
FEN1 promotes tumor progression and confers cisplatin resistance in non‐small‐cell lung cancer
por: He, Lingfeng, et al.
Publicado: (2017) -
Interacting partners of FEN1 and its role in the development of anticancer therapeutics
por: Kathera, Chandrasekhar, et al.
Publicado: (2017) -
Targeting DNA Flap Endonuclease 1 to Impede Breast Cancer Progression
por: He, Lingfeng, et al.
Publicado: (2016) -
RNA G-Quadruplex within the 5′-UTR of FEN1 Regulates mRNA Stability under Oxidative Stress
por: Ma, Ying, et al.
Publicado: (2023) -
Small-Molecule Inhibitors Targeting FEN1 for Cancer Therapy
por: Yang, Fan, et al.
Publicado: (2022)